Cargando…
P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY
Autores principales: | Shotton, Rohan, Tivey, Ann, Eyre, Toby A., Lewis, David, Allchin, Rebecca, Walter, Harriet, Miall, Fiona, Zhao, Rui, Santarsieri, Anna, Mcculloch, Rory, Bishton, Mark, Willimott, Victoria, Fowler, Nicole, Bedford, Claudia, Goddard, Jack, Protheroe, Samuel, Prahladan, Mahesh, Reeve, Miriam, Paneesha, Shankara, Marr, Helen, Wilson, Jamie, Ediriwickrema, Kushani, Knott, Chloe, Wrench, David, Talbot, Georgina, Linton, Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430971/ http://dx.doi.org/10.1097/01.HS9.0000971304.81687.8d |
Ejemplares similares
-
P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY
por: Tivey, A., et al.
Publicado: (2022) -
Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax
por: Figueroa, Rocio, et al.
Publicado: (2020) -
1102. Evaluation of Vancomycin Accumulation in Patients with Obesity
por: Assadoon, Maha, et al.
Publicado: (2021) -
P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL LYMPHOMA (CITADEL-112): PRELIMINARY SAFETY RESULTS
por: Sancho, J.-M., et al.
Publicado: (2022) -
Long-Term Ibrutinib Therapy Reverses CD8(+) T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
por: Parry, Helen M., et al.
Publicado: (2019)